Extended Data Fig. 9: mRNA-1273 protects mice from upper- and lower-airway SARS-CoV-2 infection, 13 weeks post-boost.
From: SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
a, b, BALB/cJ mice were immunized at weeks 0 and 3 with 0.01 (green), 0.1 (blue), or 1 μg (red) of mRNA-1273. Age-matched naive mice (grey) served as controls. Thirteen weeks post-boost, mice were challenged with mouse-adapted SARS-CoV-2. Two days post-challenge, at peak viral load, mouse lungs (a) and nasal turbinates (b) were collected from 5 mice per group (3 mice for the 1 μg group) for analysis of viral titres. All dose levels were compared by Kruskal–Wallis ANOVA with Dunn’s multiple comparisons test. *P < 0.05. Data are presented as GMT ± geometric s.d. Dotted line represents assay limit of detection.
